20 December 2016

As leaders of a national consortium of 36 pathology departments and the Pathological Anatomy National Automated Archive (PALGA), Marjolijn Ligtenberg (photo up) and Katrien Grünberg, theme Tumors of the digestive tract received a grant of 1.1 million euro in the ZonMw program personalized medicine oncology to optimize Predictive Analysis for THerapy (PATH) in the Netherlands.

Targeted therapies are a breakthrough in cancer treatment. The big challenge is to predict which patients benefit from these expensive drugs. DNA analysis of tumor tissue is instrumental for this. Fast technological developments and complexity of these analyses demand a coordinated approach for optimal quality and access for cancer patients.

PATH

In the PATH project pathology departments and treating physicians will closely collaborate to meet these aims using the following approaches:
  1. Optimization of predictive diagnostics by innovation and continuous monitoring of diagnostic yield and turnaround times. As proof of concept, a new NGS-based approach developed at Radboudumc laboratory for tumor genetics will be implemented in multiple laboratories. The (cost-) effectiveness of this approach will be compared to other diagnostic procedures.
  2. Establishing a national expert network of multidisciplinary molecular tumor boards that translates complex or unusual DNA aberrations to personalized treatment advice, including possible enrolment in clinical trials. This network will also serve as a platform to interact with patient interest groups and other stakeholders.
  3. The clinical relevance of a large part of the combinations of DNA aberrations and drugs remains to be settled. To enhance this evaluation a synoptic reporting module will be built in PALGA, which enables coupling with treatment and response data as collected by the Netherlands Cancer Registry (at IKNL) and clinical audit registries (DICA). This module will be an indispensable link in the infrastructure for health technology assessment of targeted drugs and evaluation of care. As a first step, the effectiveness of the organization of predictive diagnostics will be evaluated.
ZonMw Goed Gebruik Geneesmiddelen, Personalized Medicine (846001001): Predictive Analysis for Therapy: PATH to Optimising Access to Personalised Cancer Therapy in the Netherlands. 

 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Nieuws home

Related news items


Radboud University and Radboud university medical center are examining demerger

9 September 2019

Stichting Katholieke Universiteit (SKU) is going to examine the possibility of the administrative demerger of Radboud University and Radboud university medical center. The aim is to make both organisations more efficient within an increasingly dynamic and complex environment.

read more

Professor Jan W.A. Smit appointed as dean/vice chair of Radboud university medical center as of 1 August 2019

27 June 2019

The Board of the Stichting Katholieke Universiteit has appointed Professor Jan Smit as vice chair of the Executive Board per 1 August 2019.

read more

1.6 million euros for Radboud university medical center in new study into shorter tuberculosis treatment

5 June 2019

The study is meant to reveal whether a shorter treatment using a new combination of four different antibiotics could be as effective as the regular, longer treatment for tuberculosis (TB).

read more

Frank Bosch, internist-intensivist at Rijnstate, appointed as Professor of Acute Internal Medicine

10 May 2019

Rijnstate’s internist-intensivist Frank Bosch has been appointed as Professor of Acute Internal Medicine at Radboud University/Radboud University medical center/Rijnstate.

read more

Ignacio Malagon, first professor of Pediatric Anaesthesiology in the Netherlands

21 January 2019

Ignacio Malagon has been appointed professor of Pediatric Anaesthesiology at Radboud University / Radboud university medical center with effect from 1 January 2019. He is the first professor in this field in the Netherlands.

read more